COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Symptom Control With or Without Docetaxel in Treating Patients With Relapsed Esophageal Cancer or Stomach Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00978549
Recruitment Status : Completed
First Posted : September 17, 2009
Last Update Posted : August 7, 2013
Information provided by:
National Cancer Institute (NCI)

Brief Summary:

RATIONALE: Analgesics, antiemetics, steroids, and radiation therapy are effective in helping to control symptoms caused by cancer. It is not yet known whether these treatments are more effective when given with or without docetaxel in treating patients with relapsed esophageal cancer or stomach cancer.

PURPOSE: This randomized phase II trial is studying symptom control given together with docetaxel to see how well it works compared with symptom control given without docetaxel in treating patients with relapsed esophageal cancer or stomach cancer.

Condition or disease Intervention/treatment Phase
Adenocarcinoma of the Gastroesophageal Junction Esophageal Cancer Gastric Cancer Nausea and Vomiting Pain Drug: docetaxel Drug: steroid therapy Other: questionnaire administration Procedure: nausea and vomiting therapy Procedure: pain therapy Procedure: quality-of-life assessment Procedure: standard follow-up care Radiation: radiation therapy Phase 3

Detailed Description:



  • To compare overall survival of patients with relapsed adenocarcinoma of the esophagus or stomach after treatment with docetaxel and active symptom control vs active symptom control alone.


  • To determine the time to documented progression in patients treated with docetaxel.
  • To assess response rates to docetaxel in patients treated with docetaxel.
  • To determine toxicity of docetaxel in patients treated with docetaxel.
  • To assess the quality of life of these patients.
  • To evaluate the health economic impact.

OUTLINE: This is a multicenter study.

Patients are stratified according to stage (locally advanced vs metastatic), site of disease (esophagus vs esophagogastric junction vs stomach), duration of response to prior chemotherapy (no response vs response duration < 3 months vs response duration 3-6 months), and ECOG performance status (0-1 vs 2). Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive docetaxel IV over 1 hour on day 1 and active symptom control (e.g., analgesics [including opioids], antiemetics, steroids, palliative radiotherapy) daily.
  • Arm II: Patients receive active symptom control as in arm I. Courses repeat every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.

Patients in arm I undergo tissue biopsy collection at baseline and after 3 courses of treatment for biomarker analysis.

Quality of life is assessed by the QLQ-C30 and QLQ-STO22 questionnaires at baseline and at 3, 6, 9, 12, 18, and 24 weeks. Health resource use is assessed by the EQ-5D questionnaire at baseline and then periodically during and after treatment.

After completion of study treatment, patients are followed up every 6 weeks for 1 year and then every 3 months thereafter.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 320 participants
Allocation: Randomized
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomised Phase III Study of Docetaxel vs Active Symptom Control in Patients With Relapsed Oesophago-gastric Adenocarcinoma
Study Start Date : April 2008
Actual Primary Completion Date : April 2010
Actual Study Completion Date : October 2010

Resource links provided by the National Library of Medicine

Drug Information available for: Docetaxel

Primary Outcome Measures :
  1. Overall survival

Secondary Outcome Measures :
  1. Time to documented progression (arm I)
  2. Response rate (arm I)
  3. Toxicity (arm I)
  4. Quality of life as assessed by EORTC QLQ-C30 and -STO22
  5. Health economic evaluation as assessed by EQ-5D

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically confirmed adenocarcinoma of the esophagus or stomach, including adenocarcinoma of the esophagogastric junction

    • Advanced disease not amenable to curative treatment
    • Documented progressive disease while receiving or within 6 months of completion of first-line chemotherapy with a platinum- and fluoropyrimidine-based therapy either for advanced disease or as neoadjuvant/perioperative therapy
  • No cerebral or leptomeningeal metastasis


  • ECOG performance status 0-2
  • Life expectancy ≥ 12 weeks
  • Hemoglobin ≥ 10 g/dL
  • WBC ≥ 3.0 x 10^9/L
  • ANC ≥ 1.5 x 10^9/L
  • Platelets ≥ 100 x 10^9/L
  • Creatinine normal OR creatinine clearance ≥ 60 mL/min
  • Total bilirubin normal
  • ALT ≤ 1.5 times upper limit of normal (ULN)
  • Alkaline phosphatase ≤ 5 times ULN
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective barrier contraception during and for 3 months after completion of treatment
  • No clinically significant peripheral neuropathy (grade 2-4)
  • No prior malignancy except for curatively treated basal cell carcinoma of the skin or cervical intraepithelial neoplasia
  • No medical or psychiatric condition that would influence the ability of patients to provide informed consent
  • No other serious or uncontrolled illness that, in the opinion of the investigator, makes it undesirable for the patient to enter the trial


  • See Disease Characteristics
  • No prior chemotherapy with taxanes

    • ≤ 1 prior chemotherapy regimen in advanced setting allowed

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00978549

Layout table for location information
United Kingdom
Bristol Haematology and Oncology Centre
Bristol, England, United Kingdom, BS2 8ED
Addenbrooke's Hospital
Cambridge, England, United Kingdom, CB2 2QQ
Warwick Medical School Clinical Trials Unit
Coventry, England, United Kingdom, CV4 7AL
St. Luke's Cancer Centre at Royal Surrey County Hospital
Guildford, England, United Kingdom, GU2 7XX
Medical Research Council Clinical Trials Unit
London, England, United Kingdom, NW1 2DA
Royal South Hants Hospital
Southampton, England, United Kingdom, SO14 0YG
Aberdeen Royal Infirmary
Aberdeen, Scotland, United Kingdom, AB25 2ZN
Velindre Cancer Center at Velindre Hospital
Cardiff, Wales, United Kingdom, CF14 2TL
Sponsors and Collaborators
Cambridge University Hospitals NHS Foundation Trust
Layout table for investigator information
Principal Investigator: Hugo Ford, MD Cambridge University Hospitals NHS Foundation Trust

Layout table for additonal information Identifier: NCT00978549    
Other Study ID Numbers: CRCA-COUGAR-02
CDR0000649670 ( Registry Identifier: PDQ (Physician Data Query) )
First Posted: September 17, 2009    Key Record Dates
Last Update Posted: August 7, 2013
Last Verified: September 2009
Keywords provided by National Cancer Institute (NCI):
nausea and vomiting
adenocarcinoma of the esophagus
adenocarcinoma of the stomach
adenocarcinoma of the gastroesophageal junction
recurrent gastric cancer
stage IIIA gastric cancer
stage IIIB gastric cancer
stage IIIC gastric cancer
stage IV gastric cancer
recurrent esophageal cancer
stage IIIA esophageal cancer
stage IIIB esophageal cancer
stage IIIC esophageal cancer
stage IV esophageal cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Stomach Neoplasms
Esophageal Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Stomach Diseases
Head and Neck Neoplasms
Esophageal Diseases
Signs and Symptoms, Digestive
Signs and Symptoms
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action